Key facts
- It has raised $200.0M; the latest was Reverse Merger ($200.0M) in Dec 2025.
- Notable investors include OrbiMed, Perceptive Advisors, Logos Capital, RTW Investments, venBio — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Yarrow Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Yarrow Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yarrow Bioscience
Operator of a biopharmaceutical company intended to create novel therapies for chronic and inflammatory diseases. The company offers a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease, enabling clinicians to utilize transformative therapeutics for the treatment of autoimmune thyroid diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Website
- yarrowbioscience.com/
- Ownership
- Privately Held (backing)
Yarrow Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yarrow Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yarrow Bioscience in its N-PORT filings yet. We sweep new filings monthly.